|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
BNC|981058522294506706
(VIAF cluster)
|
|
005
|
|
|
20230306092626.0 |
|
008
|
|
|
110405 ||acznnaabn |n aaa |
|
003
|
|
|
BNC |
|
035
|
|
|
‡a
(BNC)981058522294506706
|
|
035
|
|
|
‡a
(ES-BaCBU).a11115841
|
|
040
|
|
|
‡a
ES-BaBC
‡b
cat
‡c
ES-BaBC
|
|
100
|
1 |
|
‡a
Mansilla Laguía, Ana
|
|
670
|
|
|
‡a
Efecto del B. Cereus Var. Toyoi (Toyocerin) en los parámetros reproductivos de conejas reproductoras, DL 2007:
‡b
port. (Ana Mansilla Laguía)
|
|
024
|
7 |
|
‡a
305870143
‡2
viaf
‡1
http://viaf.org/viaf/305870143
|
|
909
|
|
|
‡a
(viaf) 305870143
‡9
1
|
|
910
|
|
|
‡a
acciondelusodeneomicinacolistinaylacombinaciondeambosantibioticoseneltratamientodediarreasenporcino
‡A
Acción del uso de neomicina, colistina y la combinación de ambos antibióticos en el tratamiento de diarreas en porcino /
‡l
spa
‡9
1
|
|
910
|
|
|
‡a
efectodelbcereusvartoyoitoyocerinenlosparametrosreproductivosdeconejasreproductoras
‡A
Efecto del B. Cereus Var. Toyoi (Toyocerin) en los parámetros reproductivos de conejas reproductoras /
‡l
spa
‡9
1
|
|
910
|
|
|
‡a
nipoxyme200mggsuspensionoralla1colistinaliquidaensuspension20
‡A
Nipoxyme 200 mg/g suspensión oral, la primera colistina líquida en suspensión (20%) /
‡l
spa
‡9
1
|
|
921
|
|
|
‡a
andersen
‡b
Andersen,
‡9
3
|
|
922
|
|
|
‡a
‡z
spc
‡9
3
|
|
930
|
|
|
‡a
ana mansilla laguia
‡c
Ana Mansilla Laguía
‡9
3
|
|
940
|
|
|
‡a
spa
‡9
3
|
|
943
|
|
|
‡a
201x
‡9
2
|
|
943
|
|
|
‡a
200x
‡9
1
|
|
944
|
|
|
‡a
am
‡9
3
|
|
951
|
|
|
‡a
andersen firma
‡A
Andersen (Firma)
‡9
2
|
|
996
|
|
|
‡2
DNB|1340854368
|
|
996
|
|
|
‡2
BNCHL|10000000000000000122644
|
|
996
|
|
|
‡2
DNB|1046458337
|
|
996
|
|
|
‡2
ISNI|000000005477466X
|
|
996
|
|
|
‡2
LC|nr 97034310
|
|
996
|
|
|
‡2
WKP|Q64590626
|
|
996
|
|
|
‡2
WKP|Q91468725
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
|
999
|
|
|
‡2
BNCBIB|991034564229706706
|
|
999
|
|
|
‡2
BNCBIB|991039060189706706
|
|
999
|
|
|
‡2
BNCBIB|991030894079706706
|
